What is the projected market valuation for the Gastrointestinal Stromal Tumors Market in 2035?

The projected market valuation for the Gastrointestinal Stromal Tumors Market in 2035 is 1.431 USD Billion. Read More

What was the market valuation for the Gastrointestinal Stromal Tumors Market in 2024?

The overall market valuation for the Gastrointestinal Stromal Tumors Market was 0.62 USD Billion in 2024. Read More

What is the expected CAGR for the Gastrointestinal Stromal Tumors Market from 2025 to 2035?

The expected CAGR for the Gastrointestinal Stromal Tumors Market during the forecast period 2025 - 2035 is 7.9%. Read More

Which companies are considered key players in the Gastrointestinal Stromal Tumors Market?

Key players in the Gastrointestinal Stromal Tumors Market include Novartis, Bristol-Myers Squibb, Pfizer, Bayer, Boehringer Ingelheim, Amgen, Eisai, Merck & Co., and AstraZeneca. Read More

What treatment segment is projected to have the highest valuation in the Gastrointestinal Stromal Tumors Market?

The Targeted Therapy segment is projected to have the highest valuation, with estimates ranging from 0.25 to 0.55 USD Billion. Read More

How does the market valuation for surgery compare to other treatment segments?

The Surgery segment had a valuation of 0.15 USD Billion in 2024, projected to increase to 0.35 USD Billion by 2035. Read More

What is the projected market size for the stomach indication in 2035?

The projected market size for the stomach indication in 2035 is expected to range from 0.25 to 0.55 USD Billion. Read More

Which end-user segment is anticipated to dominate the Gastrointestinal Stromal Tumors Market?

The Clinics and Hospitals segment is anticipated to dominate, with a projected valuation between 0.35 and 0.85 USD Billion. Read More

What diagnostic method is expected to show significant growth in the Gastrointestinal Stromal Tumors Market?

Endoscopy is expected to show significant growth, with a projected valuation ranging from 0.12 to 0.28 USD Billion. Read More

How does the market for embolization compare to other treatment options?

The Embolization segment had a valuation of 0.04 USD Billion in 2024, with projections reaching up to 0.09 USD Billion by 2035. Read More

Gastrointestinal Stromal Tumors Market

ID: MRFR/Pharma/1054-HCR

80 Pages

Nidhi Mandole

Last Updated: May 15, 2026

Global Gastrointestinal Stromal Tumors Market Research Report Information By Indication (Stomach, Small Intestine, Other Indication), Diagnosis (Endoscopic Ultrasound, Biopsy, Others), Treatment (Surgery, Targeted Therapy), and End-User– Global Forecast Till 2035

Gastrointestinal Stromal Tumors Market Infographic

Summary Table of Contents Segmentation Methodology Download PDF

Certified Researchers

Customize Report

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Treatment (USD Billion) | |
  1. 4.1.1 Radiation Therapy | |
  2. 4.1.2 Embolization | |
  3. 4.1.3 Surgery | |
  4. 4.1.4 Targeted Therapy | |
  5. 4.1.5 Ablation | |
  6. 4.1.6 Chemotherapy | |
  7. 4.1.7 Others |
2. 4.2 Healthcare, BY Indication (USD Billion) | |
  1. 4.2.1 Large Intestine | |
  2. 4.2.2 Small Intestine | |
  3. 4.2.3 Stomach | |
  4. 4.2.4 Others |
3. 4.3 Healthcare, BY Diagnosis (USD Billion) | |
  1. 4.3.1 Endoscopy | |
  2. 4.3.2 Tomography Scans of Pelvis and Abdomen | |
  3. 4.3.3 Plain Abdominal Radiography | |
  4. 4.3.4 Imaging Studies | |
  5. 4.3.5 Endoscopic Ultrasonography | |
  6. 4.3.6 Air and Barium (Double Contrast) Series | |
  7. 4.3.7 Magnetic Resonance Imaging | |
  8. 4.3.8 Others |
4. 4.4 Healthcare, BY End-User (USD Billion) | |
  1. 4.4.1 Ambulatory Surgical Centres | |
  2. 4.4.2 Clinics and Hospitals | |
  3. 4.4.3 Others |
5. 4.5 Healthcare, BY Region (USD Billion) | |
  1. 4.5.1 North America | | |
    1. 4.5.1.1 US | | |
    2. 4.5.1.2 Canada | |
  2. 4.5.2 Europe | | |
    1. 4.5.2.1 Germany | | |
    2. 4.5.2.2 UK | | |
    3. 4.5.2.3 France | | |
    4. 4.5.2.4 Russia | | |
    5. 4.5.2.5 Italy | | |
    6. 4.5.2.6 Spain | | |
    7. 4.5.2.7 Rest of Europe | |
  3. 4.5.3 APAC | | |
    1. 4.5.3.1 China | | |
    2. 4.5.3.2 India | | |
    3. 4.5.3.3 Japan | | |
    4. 4.5.3.4 South Korea | | |
    5. 4.5.3.5 Malaysia | | |
    6. 4.5.3.6 Thailand | | |
    7. 4.5.3.7 Indonesia | | |
    8. 4.5.3.8 Rest of APAC | |
  4. 4.5.4 South America | | |
    1. 4.5.4.1 Brazil | | |
    2. 4.5.4.2 Mexico | | |
    3. 4.5.4.3 Argentina | | |
    4. 4.5.4.4 Rest of South America | |
  5. 4.5.5 MEA | | |
    1. 4.5.5.1 GCC Countries | | |
    2. 4.5.5.2 South Africa | | |
    3. 4.5.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Novartis (CH) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Bristol-Myers Squibb (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Pfizer (US) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Bayer (DE) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Boehringer Ingelheim (DE) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Amgen (US) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Eisai (JP) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Merck & Co. (US) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 AstraZeneca (GB) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY TREATMENT |
7. 6.4 US MARKET ANALYSIS BY INDICATION |
8. 6.5 US MARKET ANALYSIS BY DIAGNOSIS |
9. 6.6 US MARKET ANALYSIS BY END-USER |
10. 6.7 CANADA MARKET ANALYSIS BY TREATMENT |
11. 6.8 CANADA MARKET ANALYSIS BY INDICATION |
12. 6.9 CANADA MARKET ANALYSIS BY DIAGNOSIS |
13. 6.10 CANADA MARKET ANALYSIS BY END-USER |
14. 6.11 EUROPE MARKET ANALYSIS |
15. 6.12 GERMANY MARKET ANALYSIS BY TREATMENT |
16. 6.13 GERMANY MARKET ANALYSIS BY INDICATION |
17. 6.14 GERMANY MARKET ANALYSIS BY DIAGNOSIS |
18. 6.15 GERMANY MARKET ANALYSIS BY END-USER |
19. 6.16 UK MARKET ANALYSIS BY TREATMENT |
20. 6.17 UK MARKET ANALYSIS BY INDICATION |
21. 6.18 UK MARKET ANALYSIS BY DIAGNOSIS |
22. 6.19 UK MARKET ANALYSIS BY END-USER |
23. 6.20 FRANCE MARKET ANALYSIS BY TREATMENT |
24. 6.21 FRANCE MARKET ANALYSIS BY INDICATION |
25. 6.22 FRANCE MARKET ANALYSIS BY DIAGNOSIS |
26. 6.23 FRANCE MARKET ANALYSIS BY END-USER |
27. 6.24 RUSSIA MARKET ANALYSIS BY TREATMENT |
28. 6.25 RUSSIA MARKET ANALYSIS BY INDICATION |
29. 6.26 RUSSIA MARKET ANALYSIS BY DIAGNOSIS |
30. 6.27 RUSSIA MARKET ANALYSIS BY END-USER |
31. 6.28 ITALY MARKET ANALYSIS BY TREATMENT |
32. 6.29 ITALY MARKET ANALYSIS BY INDICATION |
33. 6.30 ITALY MARKET ANALYSIS BY DIAGNOSIS |
34. 6.31 ITALY MARKET ANALYSIS BY END-USER |
35. 6.32 SPAIN MARKET ANALYSIS BY TREATMENT |
36. 6.33 SPAIN MARKET ANALYSIS BY INDICATION |
37. 6.34 SPAIN MARKET ANALYSIS BY DIAGNOSIS |
38. 6.35 SPAIN MARKET ANALYSIS BY END-USER |
39. 6.36 REST OF EUROPE MARKET ANALYSIS BY TREATMENT |
40. 6.37 REST OF EUROPE MARKET ANALYSIS BY INDICATION |
41. 6.38 REST OF EUROPE MARKET ANALYSIS BY DIAGNOSIS |
42. 6.39 REST OF EUROPE MARKET ANALYSIS BY END-USER |
43. 6.40 APAC MARKET ANALYSIS |
44. 6.41 CHINA MARKET ANALYSIS BY TREATMENT |
45. 6.42 CHINA MARKET ANALYSIS BY INDICATION |
46. 6.43 CHINA MARKET ANALYSIS BY DIAGNOSIS |
47. 6.44 CHINA MARKET ANALYSIS BY END-USER |
48. 6.45 INDIA MARKET ANALYSIS BY TREATMENT |
49. 6.46 INDIA MARKET ANALYSIS BY INDICATION |
50. 6.47 INDIA MARKET ANALYSIS BY DIAGNOSIS |
51. 6.48 INDIA MARKET ANALYSIS BY END-USER |
52. 6.49 JAPAN MARKET ANALYSIS BY TREATMENT |
53. 6.50 JAPAN MARKET ANALYSIS BY INDICATION |
54. 6.51 JAPAN MARKET ANALYSIS BY DIAGNOSIS |
55. 6.52 JAPAN MARKET ANALYSIS BY END-USER |
56. 6.53 SOUTH KOREA MARKET ANALYSIS BY TREATMENT |
57. 6.54 SOUTH KOREA MARKET ANALYSIS BY INDICATION |
58. 6.55 SOUTH KOREA MARKET ANALYSIS BY DIAGNOSIS |
59. 6.56 SOUTH KOREA MARKET ANALYSIS BY END-USER |
60. 6.57 MALAYSIA MARKET ANALYSIS BY TREATMENT |
61. 6.58 MALAYSIA MARKET ANALYSIS BY INDICATION |
62. 6.59 MALAYSIA MARKET ANALYSIS BY DIAGNOSIS |
63. 6.60 MALAYSIA MARKET ANALYSIS BY END-USER |
64. 6.61 THAILAND MARKET ANALYSIS BY TREATMENT |
65. 6.62 THAILAND MARKET ANALYSIS BY INDICATION |
66. 6.63 THAILAND MARKET ANALYSIS BY DIAGNOSIS |
67. 6.64 THAILAND MARKET ANALYSIS BY END-USER |
68. 6.65 INDONESIA MARKET ANALYSIS BY TREATMENT |
69. 6.66 INDONESIA MARKET ANALYSIS BY INDICATION |
70. 6.67 INDONESIA MARKET ANALYSIS BY DIAGNOSIS |
71. 6.68 INDONESIA MARKET ANALYSIS BY END-USER |
72. 6.69 REST OF APAC MARKET ANALYSIS BY TREATMENT |
73. 6.70 REST OF APAC MARKET ANALYSIS BY INDICATION |
74. 6.71 REST OF APAC MARKET ANALYSIS BY DIAGNOSIS |
75. 6.72 REST OF APAC MARKET ANALYSIS BY END-USER |
76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
77. 6.74 BRAZIL MARKET ANALYSIS BY TREATMENT |
78. 6.75 BRAZIL MARKET ANALYSIS BY INDICATION |
79. 6.76 BRAZIL MARKET ANALYSIS BY DIAGNOSIS |
80. 6.77 BRAZIL MARKET ANALYSIS BY END-USER |
81. 6.78 MEXICO MARKET ANALYSIS BY TREATMENT |
82. 6.79 MEXICO MARKET ANALYSIS BY INDICATION |
83. 6.80 MEXICO MARKET ANALYSIS BY DIAGNOSIS |
84. 6.81 MEXICO MARKET ANALYSIS BY END-USER |
85. 6.82 ARGENTINA MARKET ANALYSIS BY TREATMENT |
86. 6.83 ARGENTINA MARKET ANALYSIS BY INDICATION |
87. 6.84 ARGENTINA MARKET ANALYSIS BY DIAGNOSIS |
88. 6.85 ARGENTINA MARKET ANALYSIS BY END-USER |
89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT |
90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY INDICATION |
91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY DIAGNOSIS |
92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END-USER |
93. 6.90 MEA MARKET ANALYSIS |
94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT |
95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY INDICATION |
96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY DIAGNOSIS |
97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY END-USER |
98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT |
99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY INDICATION |
100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY DIAGNOSIS |
101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY END-USER |
102. 6.99 REST OF MEA MARKET ANALYSIS BY TREATMENT |
103. 6.100 REST OF MEA MARKET ANALYSIS BY INDICATION |
104. 6.101 REST OF MEA MARKET ANALYSIS BY DIAGNOSIS |
105. 6.102 REST OF MEA MARKET ANALYSIS BY END-USER |
106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
107. 6.104 RESEARCH PROCESS OF MRFR |
108. 6.105 DRO ANALYSIS OF HEALTHCARE |
109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
112. 6.109 HEALTHCARE, BY TREATMENT, 2024 (% SHARE) |
113. 6.110 HEALTHCARE, BY TREATMENT, 2024 TO 2035 (USD Billion) |
114. 6.111 HEALTHCARE, BY INDICATION, 2024 (% SHARE) |
115. 6.112 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Billion) |
116. 6.113 HEALTHCARE, BY DIAGNOSIS, 2024 (% SHARE) |
117. 6.114 HEALTHCARE, BY DIAGNOSIS, 2024 TO 2035 (USD Billion) |
118. 6.115 HEALTHCARE, BY END-USER, 2024 (% SHARE) |
119. 6.116 HEALTHCARE, BY END-USER, 2024 TO 2035 (USD Billion) |
120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
121. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY END-USER, 2025-2035 (USD Billion) |
123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY END-USER, 2025-2035 (USD Billion) |
124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY END-USER, 2025-2035 (USD Billion) |
125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY END-USER, 2025-2035 (USD Billion) |
126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY END-USER, 2025-2035 (USD Billion) |
127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY END-USER, 2025-2035 (USD Billion) |
128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY END-USER, 2025-2035 (USD Billion) |
129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY END-USER, 2025-2035 (USD Billion) |
130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY END-USER, 2025-2035 (USD Billion) |
131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY END-USER, 2025-2035 (USD Billion) |
132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY END-USER, 2025-2035 (USD Billion) |
133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY END-USER, 2025-2035 (USD Billion) |
134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY END-USER, 2025-2035 (USD Billion) |
135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY END-USER, 2025-2035 (USD Billion) |
136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY END-USER, 2025-2035 (USD Billion) |
137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY END-USER, 2025-2035 (USD Billion) |
138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY END-USER, 2025-2035 (USD Billion) |
139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY END-USER, 2025-2035 (USD Billion) |
140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY END-USER, 2025-2035 (USD Billion) |
141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY END-USER, 2025-2035 (USD Billion) |
142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY END-USER, 2025-2035 (USD Billion) |
143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY END-USER, 2025-2035 (USD Billion) |
144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY END-USER, 2025-2035 (USD Billion) |
145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY END-USER, 2025-2035 (USD Billion) |
146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY END-USER, 2025-2035 (USD Billion) |
147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY END-USER, 2025-2035 (USD Billion) |
148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY END-USER, 2025-2035 (USD Billion) |
149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY END-USER, 2025-2035 (USD Billion) |
150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY END-USER, 2025-2035 (USD Billion) |
151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
152. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Treatment (USD Billion, 2025-2035)

Radiation Therapy
Embolization
Surgery
Targeted Therapy
Ablation
Chemotherapy
Others

Healthcare By Indication (USD Billion, 2025-2035)

Large Intestine
Small Intestine
Stomach
Others

Healthcare By Diagnosis (USD Billion, 2025-2035)

Endoscopy
Tomography Scans of Pelvis and Abdomen
Plain Abdominal Radiography
Imaging Studies
Endoscopic Ultrasonography
Air and Barium (Double Contrast) Series
Magnetic Resonance Imaging
Others

Healthcare By End-User (USD Billion, 2025-2035)

Ambulatory Surgical Centres
Clinics and Hospitals
Others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”